Conference Coverage

AHA: Empagliflozin for T2D reduces heart failure endpoints

Publish date: November 25, 2015

 

AT THE AHA SCIENTIFIC SESSIONS

References

Dr. Inzucchi disclosed ties with Boehringer Ingelheim, Merck, Janssen, Novo Nordisk, Sanofi/Regeron, Intarcia, Lexicon, Paxel, Takeda, and Eli Lilly. He acknowledged CME funding to Yale University from Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Abbot, Merck Sharp & Dohme, and Sanofi.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

EASD: Studies slam cardiovascular safety of sulfonylureas
MDedge Cardiology
TCT: Everolimus stents best paclitaxel for diabetes patients
MDedge Cardiology
EASD: Evolocumab shows ‘promising efficacy’ in type 2 diabetes
MDedge Cardiology
EADV: Hidradenitis suppurativa carries high cardiovascular risk
MDedge Cardiology
Researchers highlight gaps in diabetes screening in patients on antipsychotics
MDedge Cardiology
AHA: Homemade meals cut type 2 diabetes risk by 13%
MDedge Cardiology
Empagliflozin benefited type 2 diabetes patients with CKD
MDedge Cardiology
VIDEO: Study shows how to stand up to the ‘sitting disease’
MDedge Cardiology
AHA: Broadening evidence for CABG over PCI in diabetics
MDedge Cardiology
Blood pressure above 140/80 worsens proteinuric diabetic kidney disease
MDedge Cardiology

Related Articles